Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Pediatr Nephrol. 2023 Nov;38(11):3513-3518. doi: 10.1007/s00467-023-05928-8. Epub 2023 Mar 23.
Nephrotic syndrome (NS) consists of the clinical triad of hypoalbuminaemia, high levels of proteinuria and oedema, and describes a heterogeneous group of disease processes with different underlying drivers. The existence of circulating factor disease (CFD) as a driver of NS has been epitomised by a subset of patients who exhibit disease recurrence after transplantation, alongside laboratory work. Several circulating factors have been proposed and studied, broadly grouped into protease components such as soluble urokinase-type plasminogen activator (suPAR), hemopexin (Hx) and calcium/calmodulin-serine protease kinase (CASK), and other circulating proteases, and immune components such as TNF-α, CD40 and cardiotrophin-like cytokine-1 (CLC-1). While currently there is no definitive way of assessing risk of CFD pre-transplantation, promising work is emerging through the study of 'multi-omic' bioinformatic data from large national cohorts and biobanks.
肾病综合征 (NS) 包括低白蛋白血症、蛋白尿和水肿的临床三联征,描述了一组具有不同潜在驱动因素的异质性疾病过程。循环因子疾病 (CFD) 作为 NS 的驱动因素的存在,在一组患者中得到了体现,这些患者在移植后表现出疾病复发,同时还有实验室工作。已经提出并研究了几种循环因子,大致分为蛋白酶成分,如可溶性尿激酶型纤溶酶原激活物 (suPAR)、血红素结合蛋白 (Hx) 和钙/钙调蛋白-丝氨酸蛋白酶激酶 (CASK),以及其他循环蛋白酶,和免疫成分,如 TNF-α、CD40 和心营养素样细胞因子-1 (CLC-1)。虽然目前还没有明确的方法可以在移植前评估 CFD 的风险,但通过对大型国家队列和生物库的“多组学”生物信息学数据进行研究,正在出现有希望的工作。